FDMT – 4d molecular therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]
4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease [Yahoo! Finance]
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
4DMT Announces New Employment Inducement Grants
Form 3 4D Molecular Therapeutic For: Dec 09 Filed by: Simms Christopher Paul
Form 4 4D Molecular Therapeutic For: Dec 16 Filed by: Bizily Scott
Form 4 4D Molecular Therapeutic For: Dec 12 Filed by: THEUER CHARLES
Form 144 4D Molecular Therapeutic Filed by: Bizily Scott
Form 4 4D Molecular Therapeutic For: Dec 09 Filed by: Humer Kristian
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.